Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 11/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | BDKRB2 | P30411 | 3/20 | 0.39 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.39 |
| ▸ | MMP8 | P22894 | 1/20 | 0.37 |
| ▸ | MMP12 | P39900 | 1/20 | 0.37 |
| ▸ | MMP13 | P45452 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2338647 | 0.84 | BDKRB2 (0.46) | RORCBDKRB2BDKRB1POLB | |
| SCHEMBL2638880 | 0.84 | RORC (0.55) | RORCBDKRB2 | |
| SCHEMBL2638878 | 0.73 | RORC (0.56) | RORCBDKRB2 | |
| SCHEMBL6946090 | 0.71 | RORC (0.83) | RORCBDKRB2 | |
| SCHEMBL3743960 | 0.71 | RORC (0.83) | RORCBDKRB2 | |
| SCHEMBL31644728 | 0.69 | MMP8 (0.52) | RORCLMNAMMP8MMP12MMP13 | |
| SCHEMBL1772541 | 0.69 | BDKRB2 (0.54) | RORCBDKRB2POLB | |
| SCHEMBL7812550 | 0.69 | BDKRB2 (0.59) | RORCBDKRB2BDKRB1 | |
| SCHEMBL7815324 | 0.67 | RORC (0.51) | RORCBDKRB2BDKRB1MMP8MMP12 | |
| SCHEMBL2706478 | 0.66 | TSHR (0.60) | MMP8MMP12MMP13POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221039-A1 | Kinin Antagonists For Treating Bladder Dysfunction | JERINI AG (DE) | 2008-09-11 | — | — | US | claimed |
| EP-1901775-A2 | KININ ANTAGONISTS FOR TREATING BLADDER DYSFUNCTION | Jerini AG (DE) | 2008-03-26 | — | — | EP | claimed |
| WO-2007003411-A2 | KININ ANTAGONISTS FOR TREATING BLADDER DYSFUNCTION | JERINI AG (DE) | 2007-01-11 | — | — | WO | claimed |
| EP-1741444-A1 | Kinin antagonists for treating bladder dysfunction | Jerini AG (DE) | 2007-01-10 | — | — | EP | claimed |
| US-20080221039-A1 | Kinin Antagonists For Treating Bladder Dysfunction | JERINI AG (DE) | 2008-09-11 | — | — | US | disclosed |
| EP-1901775-A2 | KININ ANTAGONISTS FOR TREATING BLADDER DYSFUNCTION | Jerini AG (DE) | 2008-03-26 | — | — | EP | disclosed |
| WO-2007003411-A2 | KININ ANTAGONISTS FOR TREATING BLADDER DYSFUNCTION | JERINI AG (DE) | 2007-01-11 | — | — | WO | disclosed |
| EP-1741444-A1 | Kinin antagonists for treating bladder dysfunction | Jerini AG (DE) | 2007-01-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221039-A1 | Kinin Antagonists For Treating Bladder Dysfunction | BDKRB2, BDKRB1, F2R | RORC 4878/4885LMNA 3313/4885BDKRB2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.